References
1. Aboyans V, Ricco JB, Bartelink ML, et al. [2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)].Kardiol Pol . 2017;75(11):1065-1160. Wytyczne ESC dotyczace rozpoznawania i leczenia chorob tetnic obwodowych w 2017 roku, przygotowane we wspolpracy z ESVS. doi:10.5603/KP.2017.0216
2. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J . Sep 21 2017;38(36):2739-2791. doi:10.1093/eurheartj/ehx391
3. Valgimigli M, Bueno H, Byrne RA, et al. [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.]. Kardiol Pol . 2017;75(12):1217-1299. Uaktualnione stanowisko ESC dotyczace stosowania podwojnej terapii przeciwplytkowej w chorobie wiencowej w 2017 roku, przygotowane we wspolpracy z EACTS. doi:10.5603/KP.2017.0224
4. Ricotta JJ, Aburahma A, Ascher E, et al. Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease: executive summary. J Vasc Surg . Sep 2011;54(3):832-6. doi:10.1016/j.jvs.2011.07.004
5. Hansen ML, Sorensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med . Sep 13 2010;170(16):1433-41. doi:10.1001/archinternmed.2010.271
6. van Rein N, Heide-Jorgensen U, Lijfering WM, Dekkers OM, Sorensen HT, Cannegieter SC. Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapy. Circulation . Feb 5 2019;139(6):775-786. doi:10.1161/CIRCULATIONAHA.118.036248
7. Piazza G, Nguyen TN, Cios D, et al. Anticoagulation-associated adverse drug events. Am J Med . Dec 2011;124(12):1136-42. doi:10.1016/j.amjmed.2011.06.009
8. Franchi C, Antoniazzi S, Proietti M, Nobili A, Mannucci PM, Collaborators S-A. Appropriateness of oral anticoagulant therapy prescription and its associated factors in hospitalized older people with atrial fibrillation. Br J Clin Pharmacol . Sep 2018;84(9):2010-2019. doi:10.1111/bcp.13631
9. Moudallel S, Steurbaut S, Cornu P, Dupont A. Appropriateness of DOAC Prescribing Before and During Hospital Admission and Analysis of Determinants for Inappropriate Prescribing. Front Pharmacol . 2018;9:1220. doi:10.3389/fphar.2018.01220
10. Zhang ZX, van de Garde EMW, Sohne M, Harmsze AM, van den Broek MPH. Quality of clinical direct oral anticoagulant prescribing and identification of risk factors for inappropriate prescriptions. Br J Clin Pharmacol . Aug 2020;86(8):1567-1574. doi:10.1111/bcp.14264
11. Dreijer AR, Diepstraten J, Bukkems VE, et al. Anticoagulant medication errors in hospitals and primary care: a cross-sectional study. Int J Qual Health Care . Jun 1 2019;31(5):346-352. doi:10.1093/intqhc/mzy177
12. Bordet R, Gautier S, Le Louet H, Dupuis B, Caron J. Analysis of the direct cost of adverse drug reactions in hospitalised patients.Eur J Clin Pharmacol . Mar 2001;56(12):935-41. doi:10.1007/s002280000260
13. van der Hooft CS, Dieleman JP, Siemes C, et al. Adverse drug reaction-related hospitalisations: a population-based cohort study.Pharmacoepidemiol Drug Saf . Apr 2008;17(4):365-71. doi:10.1002/pds.1565
14. Leendertse AJ, Egberts AC, Stoker LJ, van den Bemt PM, Group HS. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med . Sep 22 2008;168(17):1890-6. doi:10.1001/archinternmed.2008.3
15. Essebag V, AlTurki A, Proietti R, et al. Concomitant anti-platelet therapy in warfarin-treated patients undergoing cardiac rhythm device implantation: A secondary analysis of the BRUISE CONTROL trial.Int J Cardiol . Aug 1 2019;288:87-93. doi:10.1016/j.ijcard.2019.04.066
16. Kilic S, Celik A, Cekirdekci E, et al. The Prevalence and Risks of Inappropriate Combination of Aspirin and Warfarin in Clinical Practice: Results From WARFARIN-TR Study. Balkan Med J . Jan 1 2019;36(1):17-22. doi:10.4274/balkanmedj.2017.1472
17. So CH, Eckman MH. Combined aspirin and anticoagulant therapy in patients with atrial fibrillation. Journal of thrombosis and thrombolysis . 2017;43(1):7-17.
18. De Caterina R, Ammentorp B, Darius H, et al. Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe.Heart . 2014;100(20):1625-1635.
19. Watanabe E, Yamamoto M, Kodama I, et al. Net clinical benefit of adding aspirin to warfarin in patients with atrial fibrillation: Insights from the J-RHYTHM Registry. Int J Cardiol . Jun 1 2016;212:311-7. doi:10.1016/j.ijcard.2016.03.008
20. van Uden R, van den Broek MPH, Houtenbos I, et al. Unintentional guideline deviations in hospitalized patients with two or more antithrombotic agents: an intervention study. Eur J Clin Pharmacol . Jul 28 2021;doi:10.1007/s00228-021-03185-y
21. Eyileten C, Postula M, Jakubik D, et al. Non-Vitamin K Oral Anticoagulants (NOAC) Versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type. J Clin Med . Apr 14 2020;9(4)doi:10.3390/jcm9041120
22. Gargiulo G, Goette A, Tijssen J, et al. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Eur Heart J . Dec 7 2019;40(46):3757-3767. doi:10.1093/eurheartj/ehz732
23. Lopes RD, Heizer G, Aronson R, et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med . Apr 18 2019;380(16):1509-1524. doi:10.1056/NEJMoa1817083
24. Dreijer AR, Kruip M, Diepstraten J, et al. Effect of antithrombotic stewardship on the efficacy and safety of antithrombotic therapy during and after hospitalization. PLoS One . 2020;15(6):e0235048. doi:10.1371/journal.pone.0235048